Innoblative

Innoblative is a private medical device company addressing clinical unmet needs for patients with breast cancer and other soft tissue diseases. We are developing advanced energy-based surgical solutions to help improve the way surgeons coagulate and ablate soft tissue to achieve better care for patients. Innoblative has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the company’s SIRA® RFA Electrosurgical Device. The SIRA® device is investigational for use in BCS and is not yet available for sale in the United States. The SIRA® device is cleared for intraoperative coagulation and ablation of soft tissue.